The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis

SpringerPlus

Volumn 5, Issue 1, 2016, Pages

  Siddiqui, Kashif ^a   Gold, Linda Stein ^b   Gill, Japinder ^a  

^a PAREXEL INTERNATIONAL   (United States)

^b Sleep Disorders and Research Center   (United States)

Author keywords

Ivermectin; Papulopustular; Rosacea; Topical

Indexed keywords

EID: 84979752660     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/s40064-016-2819-8     Document Type: Article

References (50)

1. Aksoy B, Altaykan-Hapa A, Egemen D, Karagoz F, Atakan N (2010) The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 163(4):719–725
2. Baldwin HE (2010) A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis 86(5 Suppl):26–36
3. Beutner K, Calverese B (2005) A multi-center, investigator-blind clinical trial to assess the safety and efficacy of metronidazole gel 1 % as compared to metronidazole gel vehicle and metronidazole cream 1 % in the treatment of rosacea. J Am Acad Dermatol 52(Suppl. 3):10
4. Bjerke R, Fyrand O, Graupe K (1999) Double-blind comparison of azelaic acid 20 % cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 79(6):456–459
5. Bohm D, Schwanitz P, Stock GS, Schmid-Ott G, Schulz W (2014) Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med 19(5):586–591
6. Cribier B (2013) Rosacea under the microscope: characteristic histological findings. J Eur Acad Dermatol Venereol 27(11):1336–1343
7. Culp B, Scheinfeld N (2009) Rosacea: a review. P T 34(1):38–45
8. Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD (2001) Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol 45(5):723–730
9. Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D (2013a) An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 91(3 Suppl):1–8
10. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E et al (2013b) Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 92(6):277–284
11. Draelos ZD, Elewski B, Staedtler G, Havlickova B (2013) Azelaic acid foam 15 % in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis 92(6):306–317
12. Draelos Z, Elewski B, Harper J, Sand M, Staedtler G (2015) Randomized, phase III, double-blind, vehicle-controlled clinical trial to evaluate the safety and efficacy of 12 weeks of twice-daily azelaic acid foam, 15 % in papulopustular rosacea. Journal of the American Academy of Dermatology 72(5):AB59
13. Elewski BE, Fleischer AB Jr, Pariser DM (2003) A comparison of 15 % azelaic acid gel and 0.75 % metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 139(11):1444–1450
14. Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A et al (2011) Rosacea—global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 25(2):188–200
15. FDA (2014) SOOLANTRA™ (ivermectin) cream, 1 % for topical use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206255lbl.pdf
16. Fowler JF Jr (2007a) Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1 % in the treatment of rosacea. J Drugs Dermatol 6(6):641–645
17. Fowler JF Jr (2007b) Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1 % in the treatment of rosacea. J Drugs Dermatol 6(6):641–645
18. Galderma (2006) A randomized, six-arm, dose-ranging, multi-center, investigator-blind, placebo and active comparator controlled trial to select the dose and regimen of Ivermectin (CD5024) according to the dose-response relationship. RD.03.SRE.40027 CSR
19. Galderma (2014) CD5024 1 % cream versus metronidazole 0.75% cream in papulopustular rosacea (PPR) study (ATTRACT). RD.03.SRE.40173 CSR
20. Galderma (2015a) Galderma receives FDA approval of novel treatment option for rosacea patients. http://www.galderma.com/News/articleType/ArticleView/articleId/75/Galderma-Receives-FDA-Approval-of-Novel-Treatment-Option-for-Rosacea-Patients. Accessed Feb 2015
21. ® (ivermectin) cream 10mg/g for rosacea patients. http://www.galderma.com/News/articleType/ArticleView/articleId/79/Galderma-Announces-Positive-Outcome-of-European-Decentralised-Procedure-for-Approval-of-SOOLANTRA-ivermectin-Cream-10mgg-for-Rosacea-Patients. Accessed April 2015
22. Gold LS, Kircik L, Fowler J, Tan J, Draelos Z (2014a) Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 13(3):316–323
23. Gold LS, Kircik L, Fowler J, Tan J, Draelos Z (2014b) Efficacy and safety of ivermectin 1 % cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies (18171 study). J Drugs Dermatol 13(3):316–323
24. Goldgar C, Keahey DJ, Houchins J (2009) Treatment options for acne rosacea. Am Fam Physician 80(5):461–468
25. Huynh TT (2013) Burden of disease: the psychosocial impact of rosacea on a patient’s quality of life. Am Health Drug Benefits 6(6):348–354
26. Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS et al (2010) A comparison of metronidazole 1% cream and pimecrolimus 1 % cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 35(3):251–256
27. Koch R, Wilbrand G (1999) Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea. J Eur Acad Dermatol Venerol 12(Suppl. 32):S143–S144
28. Leyden JJ (2014) Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol 13(6):685–688
29. Maddin S (1999) A comparison of topical azelaic acid 20 % cream and topical metronidazole 0.75 % cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 40(6 Pt 1):961–965
30. Maier LE (2011) Rosacea: advances in understanding pathogenesis and treatment. Clin Invest 1(5):739–755
31. Marks R, Ellis J (1971) Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 2(7733):1049–1052
32. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269
33. Moore S (2015) Face values: global perceptions survey report. Galderma, Lausanne
34. NCT00617903 (2013) Exploration of safety and efficacy of AzA 15% foam twice a day in rosacea
35. NICE (2014) NICE DSU technical support document 2: a generalised modelling framework for pairwise and network meta-analysis of randomised controlled trials
36. Powell FC (2005) Clinical practice. Rosacea. N Engl J Med 352(8):793–803
37. Pye RJ, Burton JL (1976) Treatment of rosacea by metronidazole. Lancet 1(7971):1211–1212
38. SIGN Checklist (2015) SIGN checklist: critical appraisal of randomized controlled trials
39. Stein GL, Kircik L, Fowler J, Jackson JM, Tan J et al (2014) Long-term safety of ivermectin 1 % cream vs azelaic acid 15 % gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 13(11):1380–1386
40. Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J et al (2015a) Superiority of ivermectin 1% cream over metronidazole 0.75 % cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 172(4):1103–1110
41. Taieb A, Ruzicka T, Berth-Jones J, Peirone MH, Jacovella J (2015b) Comparative efficacy and safety of ivermectin cream 1 % and metronidazole cream 0.75 % in the treatment of papulopustular rosacea. J Am Acad Dermatol 72(5):AB6
42. Tan JK, Girard C, Krol A, Murray HE, Papp KA et al (2002) Randomized placebo-controlled trial of metronidazole 1 % cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg. 6(6):529–534
43. The National Rosacea Society (2015) Skincare: sun protection and moisturizers. Available at: https://www.rosacea.org/patients/skincare/moisturizer
44. Thiboutot D, Thieroff-Ekerdt R, Graupe K (2003) Efficacy and safety of azelaic acid (15 %) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 48(6):836–845
45. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K (2008) Azelaic acid 15 % gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 7(6):541–546
46. Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M et al (2005) Combination sodium sulfacetamide 10 % and sulfur 5 % cream with sunscreens versus metronidazole 0.75 % cream for rosacea. Cutis 75(6):357–363
47. van Zuuren EJ, Kramer S, Carter B, Graber MA, Fedorowicz Z (2011) Interventions for rosacea. Cochrane Database Syst Rev (3):CD003262
48. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L (2015) Interventions for rosacea. Cochrane Database Syst Rev 4:CD003262
49. Wolf JE Jr, Del Rosso JQ (2007) The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis 79(1):73–80
50. Wolf JE Jr, Kerrouche N, Arsonnaud S (2006) Efficacy and safety of once-daily metronidazole 1 % gel compared with twice-daily azelaic acid 15 % gel in the treatment of rosacea. Cutis 77(4 Suppl):3–11